In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
- 1 October 2001
- journal article
- Published by Springer Nature in Leukemia
- Vol. 15 (10), 1517-1520
- https://doi.org/10.1038/sj.leu.2402244
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 22 references indexed in Scilit:
- Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562British Journal of Cancer, 2001
- Late cardiotoxicity of anthracyclines in children with acute leukemiaKlinische Padiatrie, 1999
- Dexrazoxane (ICRF-187)General Pharmacology: The Vascular System, 1999
- Coincident acute myelogenous leukemia and ischemic heart disease: Use of the cardioprotectant dexrazoxane during induction chemotherapyAmerican Journal of Hematology, 1998
- Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicinLeukemia, 1998
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16)Biochemical Pharmacology, 1993
- Phase II trial of ICRF-187 in children with solid tumors and acute leukemiaInvestigational New Drugs, 1991
- Potentiation of Doxorubicin Cytotoxicity by (+)-1,2-Bis-(3,5-dioxopiperazin-l-yl) Propane (ICRF-187) in Human Leukemic HL-60 CellsCancer Communications, 1990
- Reduction of daunomycin toxicity by razoxaneBritish Journal of Cancer, 1981